Studies for Newly Diagnosed Lung Cancer
Lucanix Vaccine Therapy for NSCLC (UW08006)
Phase III Lucanix™ Vaccine Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC) Following Front-Line Chemotherapy (STOP)
Investigator: Keith Eaton, MD, PhD; Conditions: Lung Neoplasm, Carcinoma, Non-Small-Cell Lung: Stage IIIA (T3,N2 Only), Carcinoma, Non-Small-Cell Lung: Stage IIIB, Carcinoma, Non-Small-Cell Lung: Stage IV; Status: Recruiting; Study ID: NCT00676507
A Phase II Selection Design of Pharmacodynamic Separation of Carboplatin/Paclitaxel (Taxol)/OSI- 774(Erlotinib (Tarceva); NSC-718781) or OSI-774 Alone in Advanced Non-Small Lung Cancer (NSCLC) Patients with Performance Status 2 (PS-2) Selected By Serum Proteomics
Investigator: Fred Appelbaum, MD; Conditions: Lung Cancer; Status: Recruiting; Study ID: NCT00661193
A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Onartuzumab (Metmab) in Combination With Gemcitabine + Cisplatin or Carboplatin as First-line Treatment for Patients With Stage IIIb or IV Squamous Non-small Cell Lung Cancer (NSCLC)
Investigator: Keith D. Eaton, MD; Conditions: Non-Small Cell Lung Cancer; Status: Recruiting; Study ID: NCT01519804
A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Metmab Vs. Placebo in Combination With Either Bevacizumab + Platinum + Paclitaxel or Pemetrexed + Platinum in Patients With Untreated Stage IIIb or IV Non-Squamous NSCLC
Investigator: Keith D. Eaton, MD; Conditions: Non-Small Cell Lung Cancer; Status: Recruiting; Study ID: NCT01496742
A Multi-arm Phase I Study of BMS-936558 in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, or Carboplatin/Paclitaxel in Subjects With Treatment-Naive Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC)
Investigator: Laura Q.M. Chow, MD; Conditions: Non-small Cell Lung Cancer; Status: Recruiting; Study ID: NCT01454102